ADB-104
Epilepsy
Pre-clinicalActive
Key Facts
About Adolore BioTherapeutics
Adolore BioTherapeutics is developing a novel neuromodulation platform centered on a proprietary gene therapy that delivers a novel CA8 therapeutic peptide directly inside targeted neurons and nerve fibers. Their lead programs target chronic osteoarthritis knee pain and the rare condition erythromelalgia, with a broader pipeline extending into epilepsy, hearing loss, and ophthalmology. The company's mission is to create safe, effective, and accessible non-opioid therapies to combat the opioid crisis by providing highly localized, disease-modifying treatments.
View full company profileTherapeutic Areas
Other Epilepsy Drugs
| Drug | Company | Phase |
|---|---|---|
| Soticlestat (TAK-935) | Takeda Pharmaceutical | Phase 3 |
| UCB4144 | UCB | Phase 2 |
| Keppra (levetiracetam) | UCB | Approved |
| NBI-921352 | Neurocrine Biosciences | Phase 2 |
| Oxtellar XR® | Supernus Pharmaceuticals | Approved/Commercial |
| ADX71149 | Addex Therapeutics | Phase 2 |
| Motpoly XR™ | Aucta Pharmaceuticals | Not Specified (Likely Phase 3/NDA) |